{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:22:10Z","timestamp":1777098130158,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007785","name":"Jinan Science and Technology Bureau","doi-asserted-by":"publisher","award":["2020-3-54"],"award-info":[{"award-number":["2020-3-54"]}],"id":[{"id":"10.13039\/100007785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27213-4","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:51:25Z","timestamp":1764939085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective analysis of the clinical efficacy of neoadjuvant chemotherapy albumin paclitaxel combined with carboplatin in the treatment of triple-negative breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Hengle","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yantao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"5","key":"27213_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.21037\/gs-20-209","volume":"9","author":"S Tang","year":"2020","unstructured":"Tang, S. et al. Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer. Gland. Surg. 9(5), 1415\u20131427 (2020).","journal-title":"Gland. Surg."},{"issue":"10","key":"27213_CR2","doi-asserted-by":"publisher","first-page":"300060520964340","DOI":"10.1177\/0300060520964340","volume":"48","author":"ZY Li","year":"2020","unstructured":"Li, Z. Y., Zhang, Z., Cao, X. Z., Feng, Y. & Ren, S. S. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis. J. Int. Med. Res. 48(10), 300060520964340 (2020).","journal-title":"J. Int. Med. Res."},{"issue":"9","key":"27213_CR3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","volume":"6","author":"KD Yu","year":"2020","unstructured":"Yu, K. D. et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 6(9), 1390\u20131396 (2020).","journal-title":"JAMA Oncol."},{"issue":"3","key":"27213_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","volume":"17","author":"M Untch","year":"2016","unstructured":"Untch, M. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. Lancet Oncol. 17(3), 345\u2013356 (2016).","journal-title":"Lancet Oncol."},{"issue":"25","key":"27213_CR5","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1200\/JCO.18.01842","volume":"37","author":"M Untch","year":"2019","unstructured":"Untch, M. et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto. J. Clin. Oncol. 37(25), 2226\u20132234. https:\/\/doi.org\/10.1200\/JCO.18.01842 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"27213_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.33830","volume":"150","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int. J. Cancer. 150(4), 654\u2013662. https:\/\/doi.org\/10.1002\/ijc.33830 (2022).","journal-title":"Int. J. Cancer."},{"key":"27213_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12916-015-0547-5","volume":"13","author":"JE Abraham","year":"2015","unstructured":"Abraham, J. E. et al. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Med. 13, 306. https:\/\/doi.org\/10.1186\/s12916-015-0547-5 (2015).","journal-title":"BMC Med."},{"key":"27213_CR8","doi-asserted-by":"publisher","unstructured":"Niu, Y.D., Zhang, Y.W., Zhu, R.J. et al.\u00a0Zhonghua Yi Xue Za Zhi. 102(29) 2290-2294 https:\/\/doi.org\/10.3760\/cma.j.cn112137-20220320-00590 (2022).","DOI":"10.3760\/cma.j.cn112137-20220320-00590"},{"issue":"3","key":"27213_CR9","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1002\/onco.13574","volume":"26","author":"Y Yuan","year":"2021","unstructured":"Yuan, Y. et al. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer. Oncologist. 26(3), e382\u2013e393. https:\/\/doi.org\/10.1002\/onco.13574 (2021).","journal-title":"Oncologist."},{"issue":"6","key":"27213_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djx258","volume":"110","author":"O Gluz","year":"2018","unstructured":"Gluz, O. et al. Comparison of neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in triple-negative breast cancer: Randomized WSG-ADAPT-TN trial results. J. Natl. Cancer Inst. 110(6), 628\u2013637. https:\/\/doi.org\/10.1093\/jnci\/djx258 (2018).","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"27213_CR11","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.26355\/eurrev_202204_28621","volume":"26","author":"C Varim","year":"2022","unstructured":"Varim, C. et al. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer. Eur. Rev. Med. Pharmacol. Sci. 26(8), 2900\u20132905. https:\/\/doi.org\/10.26355\/eurrev_202204_28621 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"27213_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2024.112365","volume":"121","author":"H Xie","year":"2024","unstructured":"Xie, H. et al. Evaluation and validation of neutrophil to albumin ratio as a promising prognostic marker for all-cause mortality in patients with cancer: A multicenter cohort study. Nutrition. 121, 112365. https:\/\/doi.org\/10.1016\/j.nut.2024.112365 (2024).","journal-title":"Nutrition."},{"issue":"19","key":"27213_CR13","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.3390\/cancers14194892","volume":"14","author":"CA Ko","year":"2022","unstructured":"Ko, C. A. et al. Prognostic value of neutrophil percentage-to-albumin ratio in patients with oral cavity cancer. Cancers (Basel). 14(19), 4892. https:\/\/doi.org\/10.3390\/cancers14194892 (2022).","journal-title":"Cancers (Basel)."},{"issue":"393","key":"27213_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2147\/BCTT.S468239","volume":"16","author":"YX Deng","year":"2024","unstructured":"Deng, Y. X. et al. Predictive value of pretreatment neutrophil to albumin ratio in response to neoadjuvant chemotherapy of breast cancer. Breast Cancer (Dove Med. Press). 16(393), 402. https:\/\/doi.org\/10.2147\/BCTT.S468239 (2024).","journal-title":"Breast Cancer (Dove Med. Press)."},{"issue":"9","key":"27213_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/CAD.0000000000000411","volume":"27","author":"B Tawfik","year":"2016","unstructured":"Tawfik, B., Mokdad, A. A., Patel, P. M., Li, H. C. & Huerta, S. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation. Anticancer Drug. 27(9), 879\u2013883. https:\/\/doi.org\/10.1097\/CAD.0000000000000411 (2016).","journal-title":"Anticancer Drug."},{"issue":"4","key":"27213_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000470900","volume":"62","author":"N Rao","year":"2017","unstructured":"Rao, N. et al. Significance of tumor-infiltrating lymphocytes and the expression of topoisomerase II\u03b1 in the prediction of the clinical outcome of patients with triple-negative breast cancer after taxane-anthracycline-based neoadjuvant chemotherapy. Chemotherapy. 62(4), 246\u2013255 (2017).","journal-title":"Chemotherapy."},{"issue":"3","key":"27213_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/japtr.JAPTR_26_20","volume":"11","author":"GE Chaudhry","year":"2020","unstructured":"Chaudhry, G. E. et al. Induction of apoptosis and role of paclitaxel-loaded hyaluronic acid-crosslinked nanoparticles in the regulation of AKT and RhoA. J. Adv. Pharm. Technol. Res. 11(3), 101\u2013106 (2020).","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"5","key":"27213_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 33(5), 534\u2013543. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.004 (2022).","journal-title":"Ann. Oncol."},{"issue":"7","key":"27213_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15(7), 747\u2013756. https:\/\/doi.org\/10.1016\/S1470-2045(14)70160-3 (2014).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27213-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27213-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:53:26Z","timestamp":1765198406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27213-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27213"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27213-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors approved the final version of the manuscript for publication in this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was approved by the Ethics Committee of the People\u2019s Hospital affiliated to Shandong First Medical University, and all the patients had signed the informed consent form. All procedures in the present study conformed to the ethical standards of the national research committee, and the Helsinki Declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"43356"}}